Joanne Mason

Yourgene Health Plc engages in the development and commercialization of genomic services and technologies. It primarily manufactures molecular diagnostic solutions for reproductive health, precision medicine and infectious diseases. It operates through the Genomic Technologies and Genomic Services segments. The Genomic Technologies segment represents the in vitro diagnostic products, software and instrumentation manufactured by the group. The Genomic Services segment operates testing laboratories in Taiwan and the UK, and provides services to clinicians, third party clinical service providers and contract research organizations. The company was founded on April 13, 2000 and is headquartered in Manchester, the United Kingdom.

Cambridge Epigenetix Ltd. provides epigenetic tools. Its TrueMethyl oxidative bisulfite sequencing, a novel technology that pioneers single-base resolution sequencing of the modified bases hydroxymethyl cytosine and methylcytosine. The firm's TrueMethyl enables analysis of the DNA methylome offers basic research, pharmaceutical discovery and diagnostics and TrueMethyl can be used with methylation arrays and targeted assays. The company was founded by Shankar Balasubramanian, Michael Booth and Bobby Yerramilli-Rao in 2012 and is headquartered in Cambridge, the United Kingdom.

Genomics England Ltd. runs and delivers 100,000 genomes project. Its flagship project sequences 100,000 genomes from NHS patients with a rare disease and their families, and patients with cancer. The company was founded by Jeremy Hunt on July 5, 2013 and is headquartered in London, the United Kingdom.

Part of Novacyt SAS, Yourgene Health UK Ltd. is a private company that engages in developing prenatal diagnostic products for molecular testing laboratories. Yourgene Health UK Ltd. is based in Manchester, UK. Yourgene Health was acquired by ViaLogy Plc on July 04, 2014 for $64.97 million. The British company was founded in 2013.